JP2017510821A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510821A5
JP2017510821A5 JP2017504617A JP2017504617A JP2017510821A5 JP 2017510821 A5 JP2017510821 A5 JP 2017510821A5 JP 2017504617 A JP2017504617 A JP 2017504617A JP 2017504617 A JP2017504617 A JP 2017504617A JP 2017510821 A5 JP2017510821 A5 JP 2017510821A5
Authority
JP
Japan
Prior art keywords
level
less
metabolites
asd
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017504617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510821A (ja
JP6550124B2 (ja
Filing date
Publication date
Priority claimed from US14/493,141 external-priority patent/US20150294081A1/en
Priority claimed from US14/633,558 external-priority patent/US9176113B1/en
Application filed filed Critical
Publication of JP2017510821A publication Critical patent/JP2017510821A/ja
Publication of JP2017510821A5 publication Critical patent/JP2017510821A5/ja
Application granted granted Critical
Publication of JP6550124B2 publication Critical patent/JP6550124B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017504617A 2014-04-11 2015-04-10 自閉症スペクトラム障害のリスクを決定するための方法およびシステム Active JP6550124B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461978773P 2014-04-11 2014-04-11
US61/978,773 2014-04-11
US201462002169P 2014-05-22 2014-05-22
US62/002,169 2014-05-22
US14/493,141 2014-09-22
US14/493,141 US20150294081A1 (en) 2014-04-11 2014-09-22 Methods and systems for determining autism spectrum disorder risk
US14/633,558 US9176113B1 (en) 2014-04-11 2015-02-27 Methods and systems for determining autism spectrum disorder risk
US14/633,558 2015-02-27
PCT/US2015/025247 WO2015157601A1 (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019120817A Division JP2019200210A (ja) 2014-04-11 2019-06-28 自閉症スペクトラム障害のリスクを決定するための方法およびシステム

Publications (3)

Publication Number Publication Date
JP2017510821A JP2017510821A (ja) 2017-04-13
JP2017510821A5 true JP2017510821A5 (https=) 2018-03-22
JP6550124B2 JP6550124B2 (ja) 2019-07-24

Family

ID=54264902

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017504617A Active JP6550124B2 (ja) 2014-04-11 2015-04-10 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2019120817A Withdrawn JP2019200210A (ja) 2014-04-11 2019-06-28 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2021042668A Pending JP2021103177A (ja) 2014-04-11 2021-03-16 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2023175239A Withdrawn JP2023178345A (ja) 2014-04-11 2023-10-10 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2025140823A Pending JP2025172836A (ja) 2014-04-11 2025-08-26 自閉症スペクトラム障害のリスクを決定するための方法およびシステム

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019120817A Withdrawn JP2019200210A (ja) 2014-04-11 2019-06-28 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2021042668A Pending JP2021103177A (ja) 2014-04-11 2021-03-16 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2023175239A Withdrawn JP2023178345A (ja) 2014-04-11 2023-10-10 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2025140823A Pending JP2025172836A (ja) 2014-04-11 2025-08-26 自閉症スペクトラム障害のリスクを決定するための方法およびシステム

Country Status (6)

Country Link
US (3) US9176113B1 (https=)
EP (2) EP3954991A3 (https=)
JP (5) JP6550124B2 (https=)
CN (2) CN106714556B (https=)
CA (3) CA3157221A1 (https=)
WO (1) WO2015157601A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016000293A (es) 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
HUE069048T2 (hu) * 2015-01-09 2025-02-28 Global Genomics Group Llc Vér alapú biomarkerek ateroszklerotikus koszorúér-betegség diagnosztizálására
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
KR102534545B1 (ko) 2015-05-22 2023-05-18 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
WO2017197252A1 (en) * 2016-05-13 2017-11-16 Stemina Biomarker Discovery, Inc. Autism subsets
WO2018089794A1 (en) * 2016-11-11 2018-05-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for changing metabolite levels in a subject
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
WO2019161383A1 (en) 2018-02-19 2019-08-22 The Regents Of The University Of Colorado, A Body Corporate Oxopiperidine quantitation by mass spectrometry
CN112689755A (zh) * 2018-09-11 2021-04-20 梅塔博隆股份有限公司 用于检测和定量微生物区系相关代谢物的质谱测定法
CN110487922B (zh) * 2018-12-17 2022-09-27 广西中烟工业有限责任公司 一种烟叶中苏糖酸和苏糖酸酯的gc-ms分析方法
CA3135587A1 (en) * 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic for maternal risk of having a child with autism spectrum disorder
EP3948277A4 (en) * 2019-04-05 2023-05-24 Arizona Board of Regents on behalf of Arizona State University METABOLITES AS DIAGNOSTICS OF AUTISTIC SPECTRUM DISEASE IN CHILDREN WITH GASTROINTESTINAL SYMPTOMS
WO2020242744A1 (en) * 2019-05-31 2020-12-03 Metabolon, Inc. Mass spectrometry assay methods for detection of metabolites
PH12021553137A1 (en) 2019-07-19 2022-07-25 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
CN112180005B (zh) * 2020-09-01 2022-10-04 上海市疾病预防控制中心 一种预测鉴定生物样本中酰基肉碱的方法及其应用
KR20230074216A (ko) * 2020-09-21 2023-05-26 몰레큘러 유 코포레이션 자폐 스펙트럼 장애의 진단 및 치료 방법
CN113539478B (zh) * 2021-06-24 2023-04-07 山西医科大学 基于代谢组学的深静脉血栓形成预测模型的建立方法
CN115938490B (zh) * 2023-03-07 2023-06-06 之江实验室 一种基于图表示学习算法的代谢物鉴定方法、系统和设备
WO2026011154A1 (en) * 2024-07-03 2026-01-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic tests for autism, gut dysbiosis, gut disorders, and neurological disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (en) 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Packaging material having excellent seal packaging property
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5686311A (en) 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
US6365593B2 (en) * 2000-04-12 2002-04-02 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
US20040121305A1 (en) 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
WO2004088309A2 (en) 2003-03-28 2004-10-14 Cantata Laboratories, Inc. Methods for diagnosing urinary tract and prostatic disorders
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
WO2006121952A2 (en) 2005-05-05 2006-11-16 The Regents Of The University Of California Diagnostic biomarkers for neurodevelopmental disorders
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
US20070255113A1 (en) 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
EP2052255A2 (en) 2006-08-18 2009-04-29 Huntington Medical Research Institutes Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
JP5306345B2 (ja) * 2007-07-26 2013-10-02 フェノメノーム ディスカバリーズ インク 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法
WO2009151967A1 (en) 2008-05-28 2009-12-17 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
GB0912685D0 (en) * 2009-07-22 2009-08-26 Imp Innovations Ltd Methods
CN105911275B (zh) * 2009-08-14 2018-06-29 加利福尼亚大学董事会 诊断自闭症的试剂盒
AU2011248464B2 (en) 2010-04-29 2016-08-11 Stemina Biomarker Discovery, Inc. Metabolic biomarkers of autism
AU2013230045A1 (en) * 2012-03-05 2014-09-11 Berg Llc Compositions and methods for diagnosis and treatment of pervasive developmental disorder
JP2015510756A (ja) 2012-03-09 2015-04-13 アンテグラージェン 自閉症のリスクを評価するため遺伝子型決定テスト
US20140045702A1 (en) * 2012-08-13 2014-02-13 Synapdx Corporation Systems and methods for distinguishing between autism spectrum disorders (asd) and non-asd development delay
WO2014036182A2 (en) * 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder

Similar Documents

Publication Publication Date Title
JP2017510821A5 (https=)
Di Minno et al. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies
Harrisberger et al. The association of the BDNF Val66Met polymorphism and the hippocampal volumes in healthy humans: a joint meta-analysis of published and new data
Nyman et al. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
JP2016520192A5 (https=)
Di Marco et al. Which Lynch syndrome screening programs could be implemented in the “real world”? A systematic review of economic evaluations
Keith et al. Comparison of methods for factor extraction for cognitive test-like data: Which overfactor, which underfactor?
BR112018015913A2 (pt) método para determinar uma variação no número de cópia de uma sequência de ácido nucleico de interesse, e, sistema para avaliar o número de cópia de uma sequência de ácido nucleico de interesse.
JP2014508298A5 (https=)
BR112015023894A2 (pt) sistema e método para determinação de propriedades de uma amostra
JP2015502740A5 (https=)
NZ629703A (en) Methods and compositions for detecting multiple analytes with a single signal
BR112015022002A2 (pt) aparelho para determinar informações de sinais vitais de um indivíduo, e método para determinar informações de sinais vitais de um indivíduo
BR112014016313A8 (pt) medições precisas de analito para tira de teste eletroquímico com base em característica(s) física(s) detectada(s) da amostra contendo o analito e parâmetros de biossensores derivados
BR112017019131A2 (pt) métodos, sistemas e mídia para proporcionar conteúdo de vídeo adequado para reprodução somente de áudio
BR112016010510A2 (pt) método, arranjo e uso do mesmo
JP2020502544A5 (https=)
AU2015254267A1 (en) Method for assessing state of differentiation of cells
Wray et al. Hepcidin detects iron deficiency in S ri L ankan adolescents with a high burden of hemoglobinopathy: A diagnostic test accuracy study
BR112012024206B8 (pt) método de detecção de células difíceis de remover hemoglobina, e método automático de quantificar células difíceis de remover hemoglobina
WO2011140483A3 (en) Validation of point-of-care test results by assessment of expected analyte relationships
JP2016501516A5 (https=)
WO2012139052A3 (en) Antibody biomarkers for diabetes
JP2018518725A5 (https=)
BR112017015925A2 (pt) interceptador de erro (interceptador de erro ("error trap") de eletrodo de referência determinado a partir de um tempo de amostragem especificado e um tempo de amostragem predeterminado